PROCEPT BioRobotics (NASDAQ: PRCT) EVP completes 5,363-share planned sale

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

PROCEPT BioRobotics Corp executive vice president and chief legal officer Alaleh Nouri reported selling a total of 5,363 shares of common stock in two open‑market transactions. The shares were sold at weighted average prices of $25.8193 for 3,031 shares and $26.1460 for 2,332 shares.

The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 4, 2025. After the transactions, Nouri directly holds 105,354 shares, indicating the sales represent a relatively small portion of her overall position.

Insider Trade Summary 10b5-1

Net Seller: 5,363 shares ($139,231)

Net Sell 2 txns

Insider Nouri Alaleh

Role EVP, CLO, CORP. SEC.

Sold 5,363 shs ($139K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,031	$25.8193	$78K
Sale	Common Stock	2,332	$26.146	$61K

Holdings After Transaction: Common Stock — 107,686 shares (Direct)

Footnotes (1)

The stock sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 4, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.025 to $26.020, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.025 to $26.450, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

03/19/2026 - 05:47 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nouri Alaleh

(Last)

(First)

(Middle)

C/O PROCEPT BIOROBOTICS CORPORATION

150 BAYTECH DRIVE

(Street)

SAN JOSE

CALIFORNIA

95134

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROCEPT BioRobotics Corp [ PRCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, CLO, CORP. SEC.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/19/2026		S⁽¹⁾		3,031	D	$25.8193⁽²⁾	107,686	D
Common Stock	03/19/2026		S⁽¹⁾		2,332	D	$26.146⁽³⁾	105,354	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The stock sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 4, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.025 to $26.020, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.025 to $26.450, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Jonathan Stone, Attorney-in-Fact for Alaleh Nouri	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PROCEPT BioRobotics (PRCT) report for Alaleh Nouri?

PROCEPT BioRobotics reported that EVP and chief legal officer Alaleh Nouri sold 5,363 common shares in two open-market transactions. The trades were executed at weighted average prices of $25.8193 and $26.1460, according to the Form 4 filing details.

At what prices did Alaleh Nouri sell PRCT shares in the latest Form 4?

Alaleh Nouri sold 3,031 PROCEPT BioRobotics shares at a weighted average price of $25.8193 and 2,332 shares at $26.1460. Footnotes note actual trades occurred in ranges between $25.025–$26.020 and $26.025–$26.450, respectively.

How many PROCEPT BioRobotics (PRCT) shares does Alaleh Nouri hold after the sale?

After the reported transactions, Alaleh Nouri directly owns 105,354 shares of PROCEPT BioRobotics common stock. This indicates the 5,363 shares sold represent only a small portion of her total reported holdings in the company following the Form 4 trades.

Was the recent PRCT insider sale by Alaleh Nouri under a Rule 10b5-1 plan?

Yes, the filing states Nouri’s stock sales were executed under a Rule 10b5-1 trading plan adopted on June 4, 2025. Such pre-arranged plans are designed to schedule trades in advance, reducing the significance of timing decisions for investors.

What is the total number of PRCT shares sold by Alaleh Nouri in this Form 4?

The Form 4 shows that Alaleh Nouri sold a total of 5,363 PROCEPT BioRobotics common shares. This total comes from two open-market sale transactions of 3,031 shares and 2,332 shares, as disclosed in the non-derivative transaction table.

What role does Alaleh Nouri hold at PROCEPT BioRobotics (PRCT)?

Alaleh Nouri serves as executive vice president, chief legal officer, and corporate secretary at PROCEPT BioRobotics. Her Form 4 filing reflects insider transactions in the company’s common stock associated with that senior leadership position and disclosed under SEC reporting rules.